At FimmCyte our vision is to develop the first disease modifying treatment for endometriosis. Every tenth woman has endometriosis, but besides pain management and surgery there are no alternatives. At FimmCyte we have developed a novel therapy which has proven to be highly effective in animal and ex-vivo models. This is the first immune based therapy for endometriosis and once successful will provide patients and healthcare providers a much-needed tool to fight this painful disease.
Our objective over the next 6-9 months is to optimize our endometriosis treatment so that it is applicable to as many women with endometriosis as possible which will be carried out by FimmCyte AG. After reaching a frozen design FimmCyte will seek to conduct first in-human studies by 2026. The team has been successful in securing prestigious accelerators support such as VentureKick III and the Bioinnovation institute bolstering FimmCyte’s position as a pioneer in the field of women’s health.
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 28.11.2022